Johnson & Johnson said its combination therapy for lung cancer outperformed AstraZeneca Plc’s blockbuster Tagrisso in a ...
Johnson & Johnson said a combination of its lung cancer drugs Rybrevant and Lazcluze kept people alive for at least a year ...
Johnson & Johnson said on Tuesday its chemotherapy-free combination treatment showed a meaningful improvement in extending ...
Lung cancer, notorious for its high mortality rates, is a leading cause of cancer-related deaths globally, with metastasis ...
Results from a study called Mariposa found a regimen of Rybrevant and Lazcluze helped patients with a common form of advanced ...
In an extremely rare case, an unnamed 69-year-old man who had cirrhosis and liver cancer underwent a liver transplant and ...
Johnson & Johnson’s combination of Rybrevant and Lazcluze has racked up an overall survival (OS) victory against ...
A TRANSPLANT recipient has died of cancer after contracting the illness from his organ donor. The unnamed patient, 69, from Arizona underwent an organ transplant to treat his liver ...
Medical advancements make early-detected cancers more manageable and treatable, with immunotherapy and CAR T cell therapy ...
The proportion of patients who have been diagnosed with cancer at an early stage in England is at its highest ever level ...
The brother of AFL WAG Kellie Finlayson was allegedly coward punched before being rushed to hospital on Saturday evening in Port Lincoln, South Australia.
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.